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Abstract  
Poly(lactic acid), which has an inherent tendency to form colloidal systems of low polydispersity,  
and alkylglyceryl-modified dextran – a material designed to combine the non-immunogenic and 
stabilising properties of dextran with the demonstrated permeation enhancing ability of 
alkylglycerols – have been combined for the development of nanoparticulate, blood brain barrier-
permeating, non-viral vectors. To this end, dextran, that had been functionalised via treatment with 
epoxide precursors of alkylglycerol, was covalently linked to poly(lactic acid) using a carbodiimide 
cross-linker to form alkylglyceryl-modified dextran-graft-poly(lactic acid). Solvent displacement and 
electrospray methods allowed the formulation of these materials into nanoparticles having a 
unimodal size distribution profile of about 100 - 200 nm and good stability at physiologically 
relevant pH (7.4). The nanoparticles were characterised in terms of hydrodynamic size (by Dynamic 
Light Scattering and Nanoparticle Tracking Analysis), morphology (by Scanning Electron 
Microscopy and Atomic Force Microscopy) and zeta potential, and their toxicity was evaluated using 
MTT and Presto Blue assays. Cellular uptake was evidenced by confocal microscopy employing 
nanoparticles that had been loaded with the easy-to-detect Rhodamine B fluorescent marker. 
Transwell-model experiments employing mouse (bEnd3) and human (hCMEC/D3) brain endothelial 
cells revealed enhanced permeation (statistically significant for hCMEC/D3) of the fluorescent 
markers in the presence of the nanoparticles. Results of studies using Electric Cell Substrate 
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Impedance Sensing suggested a transient decrease of the barrier function in an in vitro blood-brain 
barrier model following incubation with these nanoformulations. An in ovo study using 3-day 
chicken embryos indicated the absence of whole-organism acute toxicity effects. The collective in 
vitro data suggest that these alkylglyceryl-modified dextran-graft-poly(lactic acid) nanoparticles are 
promising candidates for in vivo evaluations that would test their capability to transport therapeutic 
actives to the brain.  
 
Keywords:  nanoparticles, drug delivery, butylglyceryl dextran, poly(lactic acid), alkylglycerols, 
blood-brain barrier, endothelial cells, cytotoxicity. 
 
 
Introduction 
The extent of neurodegenerative, cerebrovascular, inflammatory, neoplastic and infectious brain 
diseases is expected to rise with increasing average life expectancy and with the current advances in 
diagnostic methods.
1
 In treating brain ailments, the intravascular route appears attractive compared to 
other approaches due to the proximity of the brain parenchymal cells to brain capillaries and the 
large surface area of the brain vessel network.
2
 Transport from the blood-stream into the brain 
however is generally limited by the presence of the blood-brain barrier (BBB), which has an 
important role in maintaining the specific environment required for neuronal signalling. The 
presence of tight junctions and efflux proteins, together with processes such as selective abluminal 
transport and the flow of intracerebral fluid, act additively to restrict entry into the brain of toxins, 
xenobiotics and molecules endogenous to the circulatory system that may otherwise compromise the 
homeostasis of the neuronal environment.
3
  
Among several approaches aimed at overcoming the BBB (including osmotic opening, prodrugs, 
intracerebral implants, convection-enhanced delivery or focused ultrasound), colloidal systems such 
as nanoparticles or liposomes are now widely accepted as an effective tool for transporting essential 
actives into the brain. Although studies in this very active area of research have shown that these 
carriers may take advantage of the biochemical transport systems present at the barrier level, the 
mechanism of BBB transport is still under debate.
4-11 
Poly(lactic acid) (PLA) is commonly used for various tissue engineering and drug delivery 
applications not only due to its biodegradability, biocompatibility and to being non-immunoactive, 
but also due to its capacity to form colloidal systems of low polydispersity.
12,13
  While the 
hydrophobicity of pure PLA nanoparticles normally leads to a rapid removal from the bloodstream 
by the reticulo-endothelial system upon iv injection,
14
 this shortcoming may be addressed by 
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modification with hydrophilic materials of natural origin, such as dextran.
15-17
 Considered non-toxic 
and non-immunogenic, dextran has been used historically as a safe plasma expander
18
 and also to 
impart stabilisation in the blood-stream and “stealth” properties to injectable nanoparticles.19,20 
Among the materials investigated for enhancing drug penetration across the BBB, alkylglycerols 
have been shown to encourage a strong but transient increase in the transport of actives into the 
brain.
21-24
 If co-administered into the right internal carotid artery, the same materials have been found 
to increase brain uptake of certain antineoplastic agents (such as cisplatin and methotrexate) or 
antibiotics (such as vancomycin and gentamycin) in C6 glioma bearing rats and animals with RG2 
implanted tumours.
25,26 
Rationalised by the hypothesis that the assemblage of a drug-carrier system based on dextran that 
had been modified with alkylglyceryl moieties and the easily biodegradable poly(lactic acid) could 
promote increased drug permeability towards the brain, we report on the formulation and 
physicochemical characterisation of nanoparticulate non-viral vectors prepared from alkylglyceryl-
dextrans and poly(acrylic acid) and assess their toxicity and permeability/interaction with in vitro 
models of the BBB based on mouse and human brain capillary endothelial cells (bEnd3 and 
hCMEC/D3). 
 
Experimental  
General. Dextran from Leuconostoc (MW 6 kDa), dimethyl sulfoxide (DMSO, anhydrous, ≥ 99.9 
%), butyloxymethyloxirane (OX4, 95 %), 4-(dimethylamino) pyridine (DMAP, puriss. > 99 %), 
Zn(BF4)2, potassium tert-butoxide (t-BuOK; reagent grade > 97 %), carbonyldiimidazole (CDI, 
reagent grade), toluene (anhydrous, 99.8 %) were all obtained from Sigma Aldrich, Gillingham, UK. 
Poly(lactic acid) (PLA) with free carboxyl group (PLA-02A, MW 15 kDa) was a gift from Purac, 
Gorinchem, Netherlands. Fast green, Paraformaldehyde, Evans Blue and Rhodamine B were 
purchased from Sigma Aldrich, Gillingham, UK; Doxorubicin hydrochloride was obtained from 
LGM Pharma, Nashville, USA; non-anhydrous solvents were obtained from Fisher Scientific, 
Loughborough, UK; high purity deionised water was sourced from a PURELAB Optima lab system. 
Gentamycin was supplied from Gibco, Paisley, UK; fountain ink (India) was purchased from 
Pelikan. Unless otherwise specified, all reagents were used as obtained. Dulbecco’s Modified Eagle 
Medium (DMEM) media, TrypLE Express™, Hoechst Blue 33342, Phosphate Buffered Saline 
(PBS), and PrestoBlue assay were purchased from Invitrogen Life Technologies, Paisley, UK. 
Matrigel
 
was sourced from BD Biosciences, Plymouth, UK. EGM-2 Bullet Kit™ (containing 
Endothelial Growth Medium with SingleQuots™: growth factors, cytokines and supplements) was 
purchased from Lonza, Slough, UK. Recovery™ Cell Culture Freezing Medium, Hank’s Balanced 
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Saline Solution (HBSS), and distilled water (cell culture quality) were purchased from Gibco, 
Paisley, UK. Trypan blue, Fluorescein Isothiocyanate (FITC) labelled dextran, and L-cysteine were 
purchased from Sigma Aldrich, Gillingham, UK. Cryo-vials Greiner bio-one and sterile Nunc 96 
well-plates were obtained from Fisher Scientific, Loughborough , UK. MTT Cell Proliferation Assay 
Kit and digitonin were sourced from Invitrogen Life Technologies, Paisley, UK.  Sterile Transwell 
24 well-plates were obtained from Millipore, Livingstone, UK (Millicell-24 Cell Culture Plate; 
polyethylene terephthalate membrane; 1.0 µm; filtration surface 0.33 cm
2
; pore density 2×10
6
 cm
-2
); 
8-well 8WE10 array Electric Cell Substrate Impedance Sensing (ECIS) plates were sourced from 
Applied Biophysics, New York, USA. 
 
Thin Layer Chromatography silica gel plates F254 were obtained from Merck, London, UK. Dialysis 
was performed using Visking membrane tubing (Medicell International Ltd, London, UK) with cut-
off either at 12-14 kDa or at 3 kDa, in a discontinuous system (10.0 L deionised water, exchanged 3 
times/day). Cellulose nitrate membrane filters (0.2 µm) were obtained from Whatman, Maidstone, 
UK.  
Solvent removal under reduced pressure was performed using a Büchi Rotovapor R-200 powered 
with a Sogevac Saskia PIZ 100 vacuum pump equipped with a liquid nitrogen trap. Solvents were 
degassed using three freeze-thawing cycles. Sonication was performed using a Grant ultrasonic bath 
XB3 (Farnell, UK). Low speed centrifugation was performed using a Jouan B4i centrifuge equipped 
with a S40 rotor (4 000 rpm; 2 880 g; 15 min, unless otherwise specified). Ultracentrifugation was 
performed using a X3 Ultracentrifuge (Beckman Coulter Ltd. UK) with Ti 70.1 rotor at 20 °C in 
vacuo (40 000 rpm; 164 391 g; 30 min), and pre-centrifugation was performed with an Eppendorf 
MiniSpin centrifuge equipped with a F-45-12-11 rotor (Eppendorf UK). Freeze drying of aqueous 
samples (flash frozen using liquid nitrogen) was performed using an Edwards Micro Modulyo Freeze 
Dryer equipment (-50 °C) attached to an EDWARDS RV3 vacuum pump (4×10
-2
 mbar). Sonication 
was performed using a Grant ultrasonic bath XB3 from Farnell, UK. A high voltage power supply 
(PSIFC30R04.0-22; Glassman High Voltage Inc, USA) was employed for electrospraying 
experiments, in combination with a syringe pump Alladin 300 (World Precision Instruments, USA). 
A combined linear shaking water bath with thermostat (Grant OLS 200, Farnell, UK) was used for 
dye-release studies. A pumping device (Pneumatic PicoPump pv820, World Precision Instruments, 
USA) was used for in ovo intracardial administration via a glass micro-needle. A Vibratome Series 
1000 (Section Vibratome System) was used for microscopy sample preparations, which were 
visualised using a confocal microscope (LSM 710, ZEISS, Germany).   
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Materials were characterised by 
1
H- and 
13
C-NMR spectroscopy using a JEOL Eclipse 400+ 
instrument (Jeol, UK; 400 MHz for 
1
H- and 100 MHz for 
13
C-NMR); samples were dissolved in 
either CDCl3, D2O or DMSO-d6 employing 0.2 % TMS as a reference, and spectra were processed 
using the JEOL Delta v 5.0.2 software. FT-IR spectra were recorded using a Nicolet 6700 instrument 
(Thermo Scientific, UK) equipped with an ATR Smart Orbit™ accessory with diamond crystal, at 
128 scans and 4 cm
-1 
resolution. FTIR spectral analysis was performed using Omnic Specta 8.0 
software. Characterisation data is presented as Supplementary Material. A Lambda 650 Ultra 
Violet/Visible Spectrometer from Perkin Elmer was used for UV/VIS spectroscopy measurements 
(Perkin Elmer UV Lab software). Statistical analysis was performed using OriginPro 7 software from 
OriginLab, USA by one-way analysis of variance (ANOVA) followed by Tukey test and Bonferroni-
corrected post hoc T-test (p values were set at level 0.05, unless stated otherwise). Data are presented 
as mean ± standard deviation. 
 
Synthesis of alkylglycerol-dextran derivatives (DEX-O4 and DEX-OX 8). The synthesis of n-
alkyloxymethyloxiranes (OX-4 and OX-8) was carried out according to a method described 
previously.
27
 Dextran (1.00 g; 6.10 mmol) was dissolved in anhydrous DMSO (200 mL). The base 
(potassium tert-butoxide, either 1.36 g (12.20 mmol) or 2.72 g (22.40 mmol); or pyridine 0.96 g 
(12.20 mmol); or DMAP 1.49 g (12.20 mmol)) was dissolved in anhydrous THF (50 mL) and added 
dropwise into the DMSO solution of Dextran. The mixture was allowed to stir for 2 h before the 
dropwise addition of a solution of oxirane (OX4: 63 mmol, 9.0 mL, d=0.91; or OX8: 63 mmol, 12.6 
mL) in DMSO (20.0 mL). The reaction mixture was stirred for 48 h at room temperature (25 °C) 
then dialysed extensively (MWCO 3 kDa) against deionised water (10.0 L; exchanged 3  per day) 
for three days. The content of the dialysing membrane (approx. 400 mL) was washed with 
diethylether (3 × 150 mL) in a separation funnel, to remove water-insoluble impurities. After 
removing the traces of volatile solvents in a rotary evaporator under reduced pressure (25°C), the 
aqueous layer was lyophilised affording alkylglyceryl-modified dextrans (butylglyceryldextran 
DEX-OX4 and octylglyceryldextran DEX-OX8) as a slightly brown powder. Yields were in range 
52-73 %.  The final products were characterised with FTIR, 
1
H - and 
13
C – NMR spectroscopy. 
Synthesis of alkylglyceryl dextran-graft-poly(lactic acid) derivatives (PLA-DEX-OX4 and PLA DEX-
OX8) was carried out by a modification of Nagahama’s  procedure.16 In a reaction apparatus that was 
degassed and purged with nitrogen, poly(lactic acid) (PLA, 0.50 g, 0.033 mmol) in anhydrous 
chloroform (7.0 mL) was added drop-wise to a solution of carbodiimidazole (CDI, 0.11 g, 0.66 
mmol) in anhydrous chloroform (5.0 mL). The reaction mixture was stirred for 6 h at room 
temperature under nitrogen, and then washed with ethanol (10 mL) to remove the excess CDI and 
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imidazole. The resultant precipitate was collected by centrifugation and dried overnight in vacuo (25 
°C). The presence of the imidazoyl group in the CDI-activated PLA (yield 82-90%), obtained as 
white crystalline powder, was confirmed by 
1
H-NMR spectroscopy. In the second step alkylglyceryl-
dextran (DEX-OX4 0.20 g, 0.66 mmol, DEX-OX8, 0.24 g, 0.66 mmol) and 4-
(dimethylamino)pyridine (DMAP, 0.08 g, 0.60 mmol) were each dissolved in anhydrous DMSO (50 
mL); CDI-activated PLA (0.40 g, 0.027 mmol) was dissolved in anhydrous DMSO (50 mL) and 
added drop-wise to the DEX-OX & DMAP solution. The reaction mixture was stirred at room 
temperature for 24 h under nitrogen, after which time the reaction was stopped by adding conc. HCl 
(150 μL) to neutralise any DMAP and imidazole. The reaction mixture was dialysed against 
deionised water for 48 h then freeze-dried. The solid residue was washed thoroughly with acetone to 
remove excess PLA and with water to remove unreacted alkylglyceryl-dextran. The purified 
products (yields 68-81%) were freeze-dried and characterised by FT-IR, 
1
H- and 
13
C-NMR 
spectroscopy. 
Preparation of nanoparticles by solvent displacement. A solution of PLA-DEX-OX4 (either 0.5, 1.0, 
3.0, or 5.0 mg/mL) in DMSO (10.0 mL) was filtered through a 0.2 μm filter (PP membrane) and then 
dialysed (MWCO 12 000 Da) against deionised water for 72 h (10.0 L; exchanged 3 times per day) 
to remove the DMSO. For PLA-DEX and PLA-DEX-OX8 nanoparticles were prepared using a 
concentration of 1.0 mg/mL. After 48 h, the content of the dialysing tubing was freeze-dried and the 
solid material was redispersed as nanoparticles in PBS (0.9 % NaCl; pH 7.4) or in ultrapure water 
(conductivity 18 MΩ; pH 7.0). The suspension was centrifuged at low speed (3 000 rpm; 603 g; 5 
min, Eppendorf MiniSpin) to remove any potential large aggregates formed, and then the 
nanoparticles were analysed by Dynamic Light Scattering (DLS), Nanoparticle Tracking Analysis 
(NTA) and Electrophoretic Mobility Measurements (EPM).  
 
Preparation of nanoparticles by electrospraying. Nanoparticles from PLA-DEX-OX4 were prepared 
using a single-needle electrospray setup. A solution (1.0 mL) of PLA-DEX-OX4 in DMSO (5 % 
w/v) was infused using  a syringe pump (Alladin 300; World Precision Instruments, USA) into a 
needle which was connected to the high-voltage generator (PSIFC30R04.0-22; Glassman High 
Voltage Inc) and the sprayed material was collected onto a water surface (50 mL water, contained in 
a circular dish, surface area 143.1 cm
2
). The purification of the resulting dispersion was performed 
either via ultracentrifugation (Beckman, Rotor 70.1 Ti; 40 000 rpm; 164 391 g; 30 min; 20 °C) or via 
dialysis (for 3 days, 10.0 L of deionised water exchanged 3 x per day) and freeze-drying. The 
nanoparticles were then redispersed in ultrapure water or PBS (pH 7.4; 0.9 % saline) and the 
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suspension was centrifuged at low speed (3 000 rpm; 603 g; 3 min) to remove any potential 
aggregates prior to being analysed by DLS, EPM and NTA.  
 
Physical characterisation of nanoparticles. A Malvern Zetasizer Nano ZS instrument equipped with 
a 633 nm He-Ne laser (173° back-scattering angle detection) and controlled by Zetasizer v6.01 
software was used to determine the hydrodynamic diameter of nanoparticles; samples were analysed 
at 25 °C in triplicate using clear polycarbonate disposable cuvettes and following an equilibration 
time of 2 min. Results of cumulative analysis were expressed as Z-average mean (Z-av) and the 
polydispersity index (PDI) was also reported. Zeta potential was determined from electrophoretic 
mobility measurements (EPM) using the same instrument; for this purpose, samples were measured 
in folded capillary cells (DTS1070, Malvern) and data was processed according to Smoluchowski’s 
model (Henry’s function f(ka) = 1.5)). A MTP-2 (Multi-Purpose Titrator-2, Malvern, UK) equipped 
with a solvent degasser was employed to investigate pH dependency. Samples (10 mL each) were 
titrated automatically with aqueous NaOH solutions (5 mM and 50 mM) from pH 3 to pH 8, and 
with aqueous HCl solutions (5 and 50 mM) from pH 8 to pH 2; all solutions were filtered via 0.2 μm 
PES filters (Whatman) prior to use.  
Nanoparticle Tracking Analysis (NTA) was performed at 25 °C using a Nanosight instrument with a 
thermostatted LM-14 unit equipped with a 532 nm green laser and controlled by the NTA v2.2 
analytical software; the image capture (60 s) was achieved using a CCD Marlin camera. 
 
The nanoparticle morphology was investigated by Scanning Electron Microscopy (SEM) and Atomic 
Force Microscopy (AFM). Samples were prepared by redispersion of nanoparticles in ultrapure 
water and placing a droplet (5 L) onto mica adhered onto an aluminium stub (SEM) or adhered onto 
a nickel disk (AFM) for 2 min, followed by drying in a nitrogen flow. Samples for SEM were 
sputter-coated with Au/Pd (Ar atmosphere; 20 mA, 10
-3
 Pa, 5 min; Quorum coater Q150RES, 
Quorum Technologies Ltd., UK) and then investigated using a JEOL-JSM-6060LV SEM 
Microscope (voltage 15 kV, working distance 11 mm, spot size 40). For AFM investigations a 
MultiMode/NanoScope IV Scanning Probe Microscope (Digital Instruments, USA) was employed in 
tapping mode, in air, under ambient conditions (T = 23 °C, RH = 21%). A J-scanner (max. xy = 170 
m) and Si cantilevers with integrated tips (t = 3.5–4.5 m, l = 115–135 mm, w = 30–40 m, f0 = 
200–400 kHz, k = 20–80 N m-1, R < 10 nm; Model: RTESP, Bruker, France) and an RMS amplitude 
of 0.8 V were used. The results were analysed using Nanoscope v 710 software (Bruker).  
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Loading and release studies using fluorescent drug / markers. Fluorescein isothiocyanate (FITC), 
Rhodamine B and Doxorubicin free base were loaded following the same methods as for the 
preparation of nanoparticles (namely solvent displacement and electrospraying, as described above). 
Rhodamine B and Doxorubicin free base were dissolved in DMSO (10 % w/w in respect to the 
polymer); Doxorubicin free base was obtained from commercial hydrochloride salt by treatment with 
triethylamine followed by extraction with dichloromethane. Drug loading was determined by UV-
Vis spectroscopy following separation of nanoparticles by ultracentrifugation (40 000 rpm; 164 391 
g; 30 min, 20°C, Beckman, rotor 70.1 Ti); pellets were freeze-dried, measured for mass and 
dissolved in DMSO to determine the amount of dye by UV/Vis (measuring at 318 nm for Rhodamine 
B; 493 nm for FITC; 478 nm for Doxorubicin), and the results were plotted against calibration 
curves of the same fluorescent molecules obtained in DMSO.  
 
For release studies, the freeze-dried PLA-DEX-OX4 nanoparticles were redispersed (at a 
concentration of 1.0 mg/mL) in PBS (15 mL, pH 7.4, saline 0.9 %) and transferred into Eppendorf 
tubes (1.0 mL each) that were then incubated at 37 °C in a  shaker / water bath with thermostat. 
Tubes were then individually removed at pre-determined time points and centrifuged (13 000 rpm; 
11 336 g; 15 min; Eppendorf MiniSpin); three aliquots (0.1 mL each) were removed from the 
supernatant and placed into a 96 well-plate which was kept in the freezer (-20 °C) until all samples 
were collected, the plate was then equilibrated at 25 °C and subsequently analysed using an Optima 
fluorimeter. The release profiles of dyes in PBS were then calculated using calibration curves of the 
corresponding fluorescent molecules dissolved in PBS.  
 
In vitro cell cultures. bEnd3 immortalised mouse brain endothelial cells were obtained from the 
Health Protection Agency Culture Collections UK and  hCMEC/D3 immortalised (hTERT/SV40) 
human brain endothelial cell cells were a kind gift of Pierre-Olivier Couraud from Institut Cochin, 
INSERM, Paris, France . Cells were cultured under humidified atmosphere (hCMEC/D3 in a 
standard Mini Galaxy E incubator, bEnd3 in a Nuaire DH AUTOFLOW Air-Jacketed incubator) at 
37 C and 5 % CO2 in small T25 culturing (Fisher) flasks. Details of the culturing media are 
presented in Table S2 (Supplementary material). Nunclon F 96-well plates were sourced from 
Thermo Scientific. Cells were observed with an Olympus IX71 inverted phase microscope (images 
were taken using Olympus Soft Imaging System, UK) and with an LSM 710 confocal microscope 
(Zeiss, fluorescence excitation at 405 nm, 488 nm and 633 nm; facilitated by a Twin Gate main beam 
splitter).  Cells were counted using either a Vi-CELL
 
XR Cell Viability Analyser (Beckman Coulter, 
UK) or a haemocytometer. The analysis of well-plates was performed using a POLARstar Optima 
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(BMG Labtech) plate-reader. Electric Cell-substrate Impedance Sensing (ECIS) measurements were 
conducted with an ECIS Zθ instrument (Applied Biophysics) operating at a frequency range of 2 - 32 
kHz and using 8 well-arrays type 8W10E. 
 
Cytotoxicity assays. Nanoparticles (formulated from PLA-DEX; PLA-DEX-OX4 and PLA-DEX-
OX8) were tested for cytotoxicity against bEnd3 cells (seeding 1×10
4 
cells,) using an MTT assay. 
Nanoparticles were suspended in modified DMEM (1 mg/mL) and used to incubate with confluent 
bEnd3 cells (24 h). Sterile PBS (without nanoparticles) and Digitonin (1 % w/v in PBS) were used as 
negative and positive control, respectively (details as Supplementary material). A PrestoBlue assay 
was employed to assess the dose-dependent cytotoxicity of the same nanoformulations (0.2 – 4.0 
mg/mL) against hCMEC/D3 cells (seeding 1×10
4
 cells) at different time points (3 h and 24 h); PBS 
and Digitonin were similarly employed as negative and positive controls (details as Supplementary 
material). 
 
In-ovo toxicity investigations. Embryos in their early stage of development (embryos in Hamburger-
Hamilton HH stage 19, day 2; eggs supplied from a local farm after fertilisation and stored prior use 
at 15 °C in a cold storing room) were employed for these studies. Eggs (n = 6) were placed into an 
incubator (37 °C, 60-70 % humidity) 48 h prior to nanoformulation treatment. After 72 h in the 
incubator, a needle was inserted through the eggshell at the narrow apex to remove the excess of egg 
white. Adhesive tape was used to cover the egg on the top (to prevent the structure from collapsing) 
and a small oval window was cut into the shell, through the tape. 100 μL of gentamycin in PBS (10 
% w/v) was instilled inside the egg as an antibiotic pre-treatment prior to any manipulation. Fountain 
pen ink was then injected under the embryo to provide a contrast background for easier orientation 
and manipulation. The vitelline membrane enveloping the embryo was then cut with a forceps to 
reach the heart area. A thin glass micro-needle (diameter 25 μm) connected to a pneumatic pumping 
device was used to inject the nanoformulation into the heart of the embryo, close to aorta. 
Rhodamine B-loaded PLA-DEX-OX4 nanoformulations (5 μL; 1 mg/mL; Rhodamine loading 1.5 % 
w/w, by electrospraying) were employed for this study, with a Rhodamine B solution (5 μL; 0.015 
mg/mL) used as a control.  
A Fast Green solution (1 % v/v, 1 μL) was added to the nanoformulations prior to injection to allow 
visualising the spread of nanoparticles through the blood stream of the embryos. The egg cavity was 
instilled again with a dose of the antibiotic (as above), and the shell window was sealed with 
transparent adhesive tape. The eggs were then further incubated (37 °C, 60-70 % humidity) for 24 h 
before harvesting the embryos. The embryos were removed from the eggs and cleaned by removing 
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the rest of the vitelline membrane (by forceps), fixed for 15 min in paraformaldehyde solution in 
PBS (4 % w/v), and embedded in hot gelatine (60 °C). After storing for 2 h at 4 °C, the embryos 
were removed and sectioned using a vibratome (50 μm slices). The analysis was performed by a 
confocal microscope (using a 543 nm laser to visualise Rhodamine B). 
 
Cell uptake studies. bEnd3 cells were seeded (5.0×10
4
) onto glass cover slips previously coated with 
Matrigel 1.5 mg/mL and incubated for 24 h in 2.0 mL of modified DMEM (composition given in 
Table S2, Supplementary material) in a 6 well plate. Media was then replaced with 2.0 mL of each 
nanoformulation (2 mg of PLA-DEX-OX4 nanoparticles loaded with Rhodamine B (0.5 % w/w) 
dispersed in 2 mL of DMEM) and the cover slips were further incubated for 3 h. As control, cells 
were incubated in Rhodamine B solution of the same concentration as that of the Rhodamine present 
in the nanoformulation, namely 2.0 mL of cell media containing 0.001 mg of Rhodamine B base 
(prepared from stock solution, 1 mg/mL); a blank control was provided by incubating cells in 
DMEM without any addition of nanoparticles or dye. After incubation, cells were washed twice with 
PBS, fixed for 10 min in paraformaldehyde (4.0 % w/v) at 4 °C, permeabilised for 20 min with 
Triton X-100 (0.1 % v/v), and incubated for 40 min with nuclear counter-stain Hoechst 33342 (5.0 
μg/mL) at 25 °C. The cells were then visualised using a confocal microscope (LSM 710, Zeiss, 405 
nm for Hoechst, 543 nm for Rhodamine B). 
 
Nanoparticle-induced FITC translocation studies. Nanoparticles prepared from PLA-DEX-OX4 
were investigated for their effect on the cellular transport of FITC-labelled dextran (FITC-DEX, MW 
150 kDa) across confluent endothelial cell monolayers using a Transwell-type BBB model. 24 well 
plates Millipore Millicell (PET membrane; 1 µm pore diameter; 600 μL max volume) were washed 
twice with Hank’s Balanced Saline Solution (HBSS;500 µL) and equilibrated with water for 15 min 
at 37 °C. The filter membranes were then coated with ice-cold Matrigel (150 µL; 1.5 mg/mL) and 
incubated for 15-30 min at 37 °C to promote better cell adhesion. After coating, filters were washed 
twice with HBSS and either mouse or human brain endothelial cells were seeded (3 × 10
5
 bEnd3 
cells per well; 2 × 10
5
 hCMEC/D3 cells per well). Plates were incubated at 37 °C in corresponding 
media (details in Table 2S, Supplementary material), which was replaced every 2 days in both apical 
and receiving compartments. As a control, cells were also seeded in a standard 24 well plate to 
monitor their health and confluence (as the opacity of the Transwell filter did not allow for 
microscopy-based cell inspection). The experiments were carried out after reaching cell confluence, 
usually 3-4 days from seeding. In case of bEnd3 cells, a specific cocktail of barrier enhancers 
(consisting of 250 µM cAMP, 20 µM RO-20-1724, and 550 µM hydrocortisone) was applied after 
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24 h of cells reaching confluence. Nanoformulations containing PLA-DEX-OX4 nanoparticles in the 
concentration range 1-4 mg/mL (or PLA-DEX, 4 mg/mL, as control), dispersed in the corresponding 
media, were added to each well together with fluorescently-labelled dextran (FITC-DEX, 100 
μg/mL), and the concentration of FITC-DEX in the receiving compartment was then monitored over 
time by sampling (100 μL) at 30 min intervals from the receiving compartment and replacing the 
volume removed  with fresh media. Samples (triplicate) were collected into 96-well plates and 
analysed using a fluorescence plate reader Optima BMG (excitation 485 nm; emission 520 nm). The 
concentration of FITC-DEX was determined using a calibration curve of FITC-DEX in cell media ) 
and  was further used to calculate the apparent permeability coefficient (Papp), as described by 
Arthursson:
28
 
         
     
  
  
 
  
       
     (1) 
where: 
dQ/dt   the flux of FITC-DEX transported across the membrane (g/s);  
VR  basolateral volume (600 μL); 
A  surface area of the filter insert (0.33 cm
2
); 
C0  initial mass concentration of FITC-DEX at the apical side (100 g/mL) 
60   conversion factor (min to s)  
 
Electric Cell-Substrate Impedance Sensing (ECIS) studies. Polycarbonate 8 well arrays (Applied 
Biophysics, USA; 8W10E) were employed; the wells were washed twice with HBSS and 
equilibrated with cell culture grade water. The electrodes were stabilised by incubation with L-
cysteine (10 mM) for 15 min at 25 °C. The plates were washed again with HBSS and coated with 
Matrigel 1.5 mg/mL (incubation at 37 °C for 15 min), then washed again briefly with HBSS prior to 
seeding cells (either hCMEC/D3; 2.5 × 10
5
 cells per well, or bEnd3; 3 × 10
5 
cells per well; one well 
was left empty as control), and the plate was incubated at 37 °C. After reaching confluence (40-50 h, 
indicated by a plateau in resistance over time: ~ 1500 Ω for hCMEC/D3, and ~ 800 Ω for bEnd3 
cells), the media was replaced with a mix of fresh media (350 μl) and PBS-based nanoformulation 
(50 μl of PBS containing dispersed nanoparticles in a concentration range 1 – 4 mg/mL for PLA-
DEX-OX4, and 4 mg/mL PLA-DEX). After incubation with nanoparticles (24 h), the 
nanoformulation was removed and replaced with fresh media, and well were further monitored for 
24 h. ECIS readings were taken continuously for the whole duration of the experiment using an ECIS 
Zθ instrument (Applied Biophysics, USA) at 2 000 Hz. 
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Results and discussion 
Dextrans were modified by grafting with alkylglyceryl chains (where alkyl was either butyl, pentyl, 
or octyl) via a nucleophilic substitution reaction with the corresponding alkyloxy-substituted oxirane 
in an alkaline environment; this was followed by coupling with poly(lactic acid) using carbodiimide 
chemistry to afford alkylglyceryl-dextran-graft-poly(lactic acid), Figure 1.  
 
Figure 1 
 
The degree of substitution with alkylglyceryl chains (defined as the number of pendent chains per 
100 glucopyranose rings of dextran) was found to be directly dependent on the strength of the base 
and on the excess of oxirane employed. Various bases (pyridine, DMAP and t-BuOK) were tested: 
while pyridine’s basicity was not sufficient and DMAP yielded only low degrees of substitution (2.1-
6.6 %), best results (up to 75% degree of substitution) were obtained with t-BuOK at 48 h reaction 
time and 4 times molar excess of oxirane.  Attempts to employ Zn(BF4)2 as a catalyst in acidic 
aqueous media (pH 1, as reported in the literature for similar reactions)
29,30
 only resulted in products 
with a low degree of substitution (< 1.8 %).  Following product purification by extraction and 
dialysis, the modification of dextran with alkyl glyceryl chains was confirmed by FT-IR and 
1
H- / 
13
C-NMR spectroscopy. Introduction of alkylglyceryl chains resulted in the formation of new 
secondary alcohol and ether groups, evidenced by changes in the fingerprint region (such as the  
1127 cm
-1
 band, C–O–C; 1343 cm-1, O–C–H; 1539 cm-1 CH2 group vibration); in the 
1
H-NMR 
spectra of  alkylglyceryl-modified dextran, the resonances at 0.86 ppm (3 H; CH3), 1.29 ppm (2 H, 
CH2) and 1.45 ppm (2 H, CH2) are indicative of the presence of the alkylglyceryl modification. The 
signal of the anomeric proton (C1; 4.67 ppm) was well separated from the signals of the other 
protons of the glucopyranosyl ring (3.2–3.7 ppm), in agreement with data for similar structures 
reported in the literature;
31
 the multiplet at 4.96 ppm was assigned to the protons from the hydroxyl 
groups of dextran. 
 
The degree of substitution (expressed as number of alkylglyceryl chains per 100 glucopyranose 
units; DS%) was calculated from 
1
H-NMR spectra using Equation 2:  
                    
 
 
     
   
            (2) 
where C4’ is the integral of the signal assigned to the alkyl chain CH3 end group (0.86 ppm; Figure 
1), and C1 is the integral of the signal assigned to the anomeric proton from of the glucopyranose 
ring (4.67 ppm). 
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The degree of substitution varied widely (from 0.7 to 75.1 % for DEX-OX4, and from 16.5 to 38.2 % 
for DEX-OX8), and it was found to increase with reaction time and with the concentration of base (t-
BuOK) employed.  Since the calculated degree of substitution never exceeded 100 %, and 
considering that the OH group reactivity in dextran towards alkylation agents is known to decrease in 
the order C2 > C4 > C3
 
(likely due to the proximity to the anomeric C1 carbon),
32-35 
 it can be 
reasonably assumed that only the primary hydroxy groups were grafted with alkylglyceryl chains. 
 
Poly(lactic acid) with free carboxylic end group was attached to the alkylglyceryl-modified dextran 
using carbodiimide chemistry, with either N,N'-dicyclohexylcarbodiimide (DCC ) or N,N'-
carbonyldiimidazole (CDI). Following purification by repeated washings with water and acetone to 
remove potentially un-reacted PLA, final products were obtained after freeze-frying as off-white 
powders. Higher yields were obtained with CDI (68-81 %) than with DCC (33-56 %). Strong IR 
bands at 1751 cm
-1
 and 3352 cm
-1
 characteristic of the C=O stretching vibration in PLA and of the 
OH stretching vibrations of the dextran backbone confirmed the success of the grafting process, as 
did the 
1
H-NMR spectra, which exhibited characteristic bands for butylglyceryl-modified dextran 
(0.87 ppm; CH3 of alkylglyceryl chain; 3.22-5.14 ppm glucopyranose ring) and for poly(lactic acid) 
(1.44 ppm, CH3; 5.19 ppm, CH). A conjugate of poly(lactic acid) and unmodified dextran (PLA-
DEX) was prepared using CDI and used as control. The ratio between PLA and modified dextran 
enumerated the degree of grafting (DG; defined as the number of PLA polymeric units per 100 
glucopyranose units of dextran), which was calculated from 
1
H-NMR spectra using Equation 3 
below,  
   
 
 
  
   
             (3) 
 
where:  a integral of the signal attributed to the CH3 group in PLA (1.31 ppm) 
C1 integral of the signal attributed to the anomeric proton of dextran (4.39 - 5.17) 
 
The degree of grafting was found to decrease slightly with increasing length of the alkylglyceryl 
chain used for the hydrophobic modification of dextran: PLA-DEX (130-142 %); PLA-DEX-OX4 
(108-120 %); PLA-DEX-OX8 (88-112 %). 
 
The size range of nanoparticles prepared from PLA-DEX-OX4 by solvent displacement was found to 
be consistent with those reported in the literature for poly(lactic acid) dextran copolymers.
16,36
 The 
same parameter was found to be dependent on the concentration of polymer in the DMSO solution 
that had been subjected to dialysis (Figure 2A), with  concentrations below 6 mg/mL affording the 
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smallest particle size (diameter  120 - 160 nm). Also, no significant statistical difference was found 
in the size of nanoparticles obtained from different PLA-conjugated modified dextran polymers 
(PLA-DEX, PLA-DEX-OX4, PLA-DEX-OX8) using the solvent displacement formulation method 
at the concentration of 1.0 mg/mL (Figure 2B). 
 
Figure 2 
 
Further experiments employing electrospraying techniques where PLA-DEX-OX4 solutions in 
DMSO (50 mg/mL) were subjected to high voltage electric field resulted in the formation of particles 
at the 100 - 200 nm diameter range. As with nanoprecipitation, this technique requires post-
purification of nanoparticles either by dialysis or ultra-centrifugation. A comparison of the 
characteristics measured for the PLA-DEX-OX4 nanoparticles formulated using different methods 
(Table 1) suggests that size (as measured in PBS saline 0.9 %, at pH 7.4, by both DLS and NTA) is 
in all cases suitable for intravascular drug delivery at physiological pH,
 37
 with the solvent 
displacement method offering the advantage of higher yields. 
Table 1 
 
The pH stability of PLA-DEX-OX4 nanoformulations was investigated by titrating nanoparticles 
dispersed in ultrapure water while monitoring their size and zeta potential, which at pH 7.4 was in 
the range -15 to -30 mV for all formulations. Both average size and zeta potential were stable over a 
wide range of pH values (2 - 8), however an increase in size and a gradual agglomeration were 
noticed near the isoelectric point of poly(lactic acid), as expected from its pKa value (3.1) (Figure 3).  
Figure 3 
 
Investigations of the morphology of freeze-dried PLA-DEX-OX4 nanoparticles prepared by dialysis 
indicated a spherical shape (Figure 4) and submicron size diameter (PLA-DEX-OX4 - horizontal 
64.4 ± 11.7 nm, vertical 15.4 ± 2.2 nm); PLA-DEX - horizontal 52.5 ± 15.4 nm, vertical 14.4 ± 4.5 
nm; as measured by AFM). The difference between the vertical and horizontal dimensions of AFM 
images are attributed to the deformation induced by the pressure exerted by the tip on the probed 
nanoparticle. The aggregates observed in the SEM micrograph are assumed to have been formed 
during the evaporation of liquid media at the sample preparation stage. The differences observed 
when comparing these results with those obtained for the same type of nanoparticles in colloidal 
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form are likely due to the hydration of the outer layer and also possibly due to an induced 
conformational change of polymer chains at the surface of nanoparticles.
38
 
Figure 4 
Doxorubicin free base, Fluorescein isothiocyanate (FITC), and Rhodamine B free base were 
employed as drug models and fluorescence markers respectively. The molecules were selected due to 
their low detection limits and limited photobleaching. They were loaded into PLA-DEX-OX4 
nanoparticles prepared by either solvent displacement or by electrospraying, and drug/marker 
loading was determined by fluorescence measurements; results (Table 2) clearly indicate that 
electrospraying provides a more efficient loading method compared to solvent displacement. FITC 
was found to load poorly into PLA-DEX-OX4 nanoparticles and to be released under simulated 
physiological conditions with a burst effect that was complete within 30 min (Figure 5). In contrast, 
Rhodamine B and Doxorubicin (both as free base) showed better loading and gradual release 30 to 
50 % over several hours. 
Table 2 
Figure 5 
Despite recent drug-delivery advances that seem to hold great promise for the treatment of CNS 
diseases, very little is known about the long-term safety of nanomaterials employed in these studies, 
therefore testing the toxicity of these nanoformulations in early stages of development is of 
importance. We found that incubation of mouse brain endothelial cells bEnd3 with poly(lactic acid)-
graft-alkylglyceryldextran (PLA-DEX-OXn) nanoparticles (1 mg/mL) for 24 h revealed no 
significant toxicity induced by these nanoformulations (ANOVA p < 0.05); cell viability following 
treatment with PLA-DEX, PLA-DEX-OX4 and PLA-DEX-OX8 nanoparticles was about 90 % of 
that of a PBS control (Figure 6A). Experiments with human brain endothelial cells (hCMEC/D3) at 
different concentrations confirmed the lack of toxicity at short incubation times (3 h) and appeared to 
suggest that the alkylglyceryl modification of dextran shows a higher viability compared to PLA-
DEX (Figure 6B); however, incubation for 24 h revealed a gradual reduction in viability at doses 
higher than 2 mg/mL (ANOVA, p < 0.05) (Figure 6C).  
Figure 6 
Figure 7 
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Injections into the heart of chicken embryos with nanoformulations prepared from PLA-DEX-OX4 
and loaded with Rhodamine B showed that nanoparticles did not aggregate in circulation and did not 
affect the viability of the embryos; 100 % viability (n = 6) was observed for both control and 
nanoparticles (as evidenced by the heart function of the embryos) for the duration of the experiment 
(min. 24 h following injections). No specific patterns were observed in the biodistribution of the 
fluorescent marker, which appeared to extravasate freely into the embryo as all the endothelial 
barriers including the BBB are still leaky at this development stage.
39
 Most of the fluorescence 
appeared around blood vessels, and no significant differences were observed in the distribution of 
Rhodamine B between the two administration methods employed (i.e. as solution, or loaded into 
nanoparticles and later released during incubation; Figure 7). 
 
Nanoparticles prepared from PLA-DEX-OX4 were loaded with Rhodamine B (0.5 % w/w) and 
investigated for their interactions with bEnd3 cells after 3 h incubation in DMEM. Confocal 
microscopy indicated that Rhodamine B-loaded carriers were taken up by the bEnd3 cells as 
evidenced by the presence of the fluorescent dye in the cytoplasm and in the peri-nuclear space 
(Figure 8); there was no similar evidence of the Rhodamine B being inside cells that was used as a 
control solution. While there was no evidence of targeting the nuclei, the nanoparticles appeared to 
have been localised in vesicles (possibly Golgi apparatus, as previously demonstrated for CS-OX4 
nanoparticles).
21
  
 
Figure 8 
The effect of PLA-DEX and PLA-DEX-OX4 nanoformulations on the integrity of confluent 
endothelial cell monolayers was investigated by monitoring changes in the transendothelial 
resistance (TEER) of either mouse bEnd3 or human hCMEC/D3 cell monolayers, both during 
incubation and following removal of nanoparticles. The mouse model reached ~ 800 Ω resistance 
while the human model exhibited a resistance of ~1500 Ω when the cell cultures achieved confluence 
(ca. 48 h). Results of TEER measurements for a range of concentrations (1 to 4 mg/ml)  - presented 
as values relative to the PBS control, Figure 9 - indicated differences in the behaviour of mouse brain 
endothelial bEnd3 cells that had been treated with PLA-DEX nanoparticles as compared with those 
treated with PLA-DEX-OX4 nanoparticles; a drop in TEER values was observed for all 
concentrations of the latter. To assess the capability of cells to recover following nanoparticle-
induced stress, TEER was monitored for longer periods of time than those found in complementary 
experiments to be readily tolerated by the cells (Figure 6B). The data in Figure 9 indicate that at high 
concentrations (4 mg/ml) there is a non-reversible drop in TEER after 72 h, which may be attributed 
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to cell death (as supported by the decrease in cell viability observed at high nanoparticle 
concentrations, Figure 6C). Following nanoparticle removal, TEER levels recovered for all 
monolayers except those that had been treated with the highest dose of PLA-DEX-OX4 (significant 
statistical difference for bEnd3 cells at 72 h, ANOVA, p < 0.05, Figure 9A); this may be attributed to 
the time- and concentration-dependent toxicity of PLA-DEX-OX4 nanoparticles. No significant 
dose-response effect could be unmasked when the formulation was tested against human-brain 
endothelial hCMEC/D3 cells (Figure 9B). 
Figure 9 
 
Investigations of the capability of PLA-DEX-OX4 nanoparticles to increase drug permeability 
through mouse and human brain endothelial cell monolayers were carried out using a translocation 
model system based on a Transwell setup, where the effect of each nanoformulation was assessed 
using fluorescent FITC-labelled dextran (MW 150 kDa). In a comparison of the two types of models, 
data suggested that the bEnd3 model was more permeable than that based on hCMEC/D3 cells 
(Figure 10); the latter may therefore be more suitable for this type of permeability experiments as it 
also could reveal the concentration-dependent effect induced by PLA-DEX-OX4 nanoparticles 
(statistically significant for hCMEC/D3 cells at 4 mg/mL dose, compared with controls; ANOVA p < 
0.05). 
 Figure 10  
Translocation studies utilised the concentration of fluorescently labelled dextran (FITC-dextran) 
present in the apical compartment of the Transwell system as the indicator of the permeation 
enhancing properties of nanoparticles under investigation. The apparent permeation coefficient 
(Papp), calculated from the concentration of FITC-dextran transported across a unit surface area of 
the barrier over a specified timescale, corresponds to the translocating capacity of a cellular 
monolayer of a population of the cell culture.
28
 As determined from the amount of translocated 
FITC-DEX, the data presented in Table 3 suggest that over a 3 h incubation time PLA-DEX-OX4 
nanoparticles at high doses are more effective at modulating the permeability of hCMEC/D3 cell 
monolayers as compared with PLA-DEX nanoparticles. Since toxicity experiments have 
demonstrated that at relatively short incubation times the alkylglyceryl modification is not associated 
with any additional toxicity effects to cells (Figure 6B), the increased transport of FITC-DEX cannot 
be readily attributed to cell death (and the consequent development of “leaky holes” in the 
monolayers); increased cytotoxicity is however noticeable with high doses (4 mg/ml) at long 
incubation times (> 72 h). While PLA-DEX nanoparticles were seen to increase the transport of 
18 
 
FITC-DEX to some extent (possibly via non-specific nanoparticle-cell interaction),
40
 data appear to 
support the hypothesis that the alkylglyceryl modification could possibly increase barrier 
permeability via mediated opening of the tight junctions. This is further supported by data from ECIS 
experiments, which revealed transient drops in TEER values upon the application of nanoparticles. 
Table 3 
Lower Papp values were obtained for the hCMEC/D3 cell model than for that employing bEnd3 cells 
(Table 3), which indicates the better barrier properties of the human brain cells model. While our 
Papp values obtained with the mouse cell model were consistent with literature values (1 × 10
-7
 at 4 h 
of incubation),
41
 those for the human cell model are different.
42,43
 This may be explained in terms of 
the modifications in experimental protocol or may be consequent to the introduction of non-
physiologically relevant features into the system.
44,45 
Irrespective of the reason for this difference, 
our results indicate that the use of a barrier enhancing formulation to decrease the permeability of the 
cell monolayers is effective. 
 
Conclusions 
Alkylglyceryl-modified dextran-graft-poly(lactic acid) derivatives (PLA-DEX-OXn; prepared by the 
alkylglycerol  functionalisation of dextran and its subsequent attachment to the terminal carboxylic 
group of poly(lactic acid) by means of carbodiimide cross-linkers) can be easily formulated into 
nanoparticles that appear to be good candidates for drug delivery or for imaging applications. 
Nanoparticles of average size in the 100-200 nm range exhibited unimodal size distribution profiles, 
as determined by DLS and NTA, and a negative zeta potential, as evidenced by electrophoretic 
mobility measurements. Formulations of these nanoparticles exhibit good stability at around neutral 
pH. The relative uniformity of nanoparticle size has been confirmed in the solid state by the SEM 
and AFM imaging of freeze dried samples. These nanoparticles may be prepared using any of three 
techniques (solvent displacement, nanoprecipitation or electrospraying) and are amenable to loading 
with actives or with fluorescent markers; the electrospraying technique has been identified as 
particularly useful for the loading of Doxorubicin.  
In general, nanoformulations displayed low toxicity against mouse bEnd3 and human hCMEC/D3 
brain endothelial cells, even at relatively high doses (80 % viability for 2 mg/mL, after 24 h 
incubation).  However, over prolonged incubation times (> 72 h), doses of nanoparticles at the 4 
mg/ml level appeared to negatively affect the cell monolayers integrity. As assessed by 
investigations involving early development-stage chicken embryos, PLA-DEX-OX4 nanoparticles 
did not exhibit any propensity to aggregation in blood circulation. Alkylglyceryl functionalisation 
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has been shown to impact little upon the toxicity of nanoparticles, as assessed by comparative studies 
involving their unmodified congeners at similar concentrations. 
Microscopy investigations using bEnd3 mouse brain endothelial cells have indicated the cellular 
uptake of Rhodamine B-labelled butylglyceryl modified nanoparticles PLA-DEX-OX4 and their 
tendency to agglomerate at the perinuclear region. TEER measurements on monolayers of bEnd3 or 
hCMEC/D3 brain endothelial cells have demonstrated the capability of nanoformulations to induce 
concentration-dependent transient changes to monolayer integrity.  
The in vitro permeability of fluorescent FITC dextran through hCMEC/D3 brain endothelial cell 
monolayers has been seen to increase on co-administration with butylglyceryl modified nanoparticles 
PLA-DEX-OX4, suggesting the enhanced cellular transport of the tracer; administration of non-
modified nanoparticles PLA-DEX at the same concentration did not induce a similar effect. 
The collective in vitro data suggest that these alkylglyceryl-modified dextran-poly(lactic acid) 
nanoparticles are promising candidates for in vivo evaluations  of their capability to transport 
therapeutic actives or fluorescent markers into the brain. 
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Tables 
 
Table 1 . Characteristics of nanoparticles prepared from PLA-DEX-OX4 using different techniques 
(n = 3).  
Table 2. Loading of fluorescent molecules into PLA-DEX-OX4 nanoparticles using different 
techniques (n = 3, ±SD). 
Table 3a. Apparent permeability coefficients (Papp) for PLA-DEX and PLA-DEX-OX4 nanoparticles 
measured in human and mouse brain endothelial cell models (3 h incubation time; FITC-DEX as 
control; n=6, ±SD). 
Table 3b. Statistical significance of apparent permeability coefficients (Papp); p values indicate 
significance if  < 0.005 (Bonferroni-corrected post hoc T-test). 
 
 
 
  
21 
 
 
 
 
Table 1. Characteristics of nanoparticles prepared from PLA-DEX-OX4 (a) and PLA-DEX (b) using 
different techniques (n = 3).  
Formulation 
technique 
Diameter 
NTA  
nm ±SD 
Diameter 
DLS 
nm ±SD 
PDI (DLS) 
Zeta 
Potential 
mV ±SD 
Yields PLA-DEX-OX4 (%; 
after purification) ±SD 
(a) (b) (a) (b) (a) (b) Dialysis Centrifugation 
Solvent 
displacement 
(1 mg/mL)  
123 
±85 
113 
±23 
161 
±61 
132 
±63 
0.18 
±0.03 
0.12 
±0.09 
-22 ±7 71 ±19 13 ±5* 
Nanoprecipitation 
(5 mg/mL) 
142 
±53 
104 
±15 
152 
±48 
150 
±37 
0.15 
±0.05 
0.12 
±0.07 
-23 ±7 44 ±23 15 ±7 
Electrospraying 
(50 mg/mL) 
155 
±63 
136 
±12 
143 
±69 
141 
±51 
0.12 
±0.03 
0.17 
±0.09 
-25 ±8 61±16 20 ±13 
* n = 2  
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Table 2. Loading of fluorescent molecules into PLA-DEX-OX4 nanoparticles using different 
techniques (n = 3, ±SD). 
 
Drug loading (% mass)  
Solvent displacement  Electrospraying 
FITC 0.02 ± 0.01  -* 
Rhodamine B 0.32 ± 0.11  4.93 ± 0.76  
Doxorubicin 0.50 ± 0.23  12.57 ± 3.17  
* not measured (could not be loaded) 
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Table 3a. Apparent permeability coefficients (Papp) for PLA-DEX and PLA-DEX-OX4 nanoparticles 
measured in human (hCMEC/D3) and mouse (bEnd3) brain endothelial cell models (3 h incubation 
time; FITC-DEX as control; n=6, ±SD). 
 
 
 
 
 
 
Table 3b. Statistical significance of apparent permeability coefficients (Papp); p values indicate 
significance if  < 0.005 (Bonferroni-corrected post hoc T-test). 
 
  
Papp±SD 
[cm s
-1
] 
at 3 h 
FITC-DEX 
150 kDa 
PLA-DEX-OX4 
1 mg/mL 
PLA-DEX-OX4 
2 mg/mL 
PLA-DEX-OX4 
4 mg/mL 
PLA-DEX 
4 mg/mL 
 
bEnd3 
(1.36±0.24) 
 10-7 
(1.52±0.81) 
 10-7 
(1.70±0.51) 
 10-7 
(1.70±0.39) 
 10-7 
(1.63±0.41) 
 10-7 
 
hCMEC/D3 
(1.38±0.22) 
 10-8 
(1.22±0.09) 
 10-8 
(1.95±0.03) 
 10-8 
(2.41±0.13) 
 10-8 
(1.41±0.06) 
 10-8 
 
p values (T-test) 
FITC-DEX 
150 kDa 
PLA-DEX-OX4 
1 mg/mL 
PLA-DEX-OX4 
2 mg/mL 
PLA-DEX-OX4 
4 mg/mL 
PLA-DEX 
4 mg/mL 
 
b
E
n
d
3
 
FITC-DEX 
150 kDa -     
 
PLA-DEX-
OX4 
1 mg/mL 
0.656735031 -     
PLA-DEX-
OX4 
2 mg/mL 
0.169592255 0.651089519 -    
PLA-DEX-
OX4 
4 mg/mL 
0.095557895 0.631365511 0.996752012 -   
PLA-DEX 
4 mg/mL 0.197481850 0.776992499 0.785540214 0.754566273 - 
 
h
C
M
E
C
/D
3
 
FITC-DEX 
150 kDa 
- 
     
PLA-DEX-
OX4 
1 mg/mL 
0.134252930 -     
PLA-DEX-
OX4 
2 mg/mL 
0.000099116 0.000000005 -    
PLA-DEX-
OX4 
4 mg/mL 
0.000002102 0.000000006 0.000010315 -   
PLA-DEX 
4 mg/mL 
0.724262400 0.001501892 0.000000004 0.000000014 -  
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Figure legends 
 
Figure 1. Generic structure of alkylglyceryl-dextran-graft-poly(lactic acid) co-polymers. 
Figure 2. A) The effect of polymer concentration on the hydrodynamic diameter of nanoparticles 
formulated from PLA-DEX-OX4 via solvent displacement; B) Hydrodynamic diameter of 
nanoparticles formulated by the same method from DMSO solution (1 mg/mL) of different types of 
PLA-dextran conjugate materials. Error bars represent ±SD (n=3). 
Figure 3. Variation of PLA-DEX-OX4 nanoparticles characteristics (size and zeta potential) with 
decreasing pH (1 mg/mL dispersion prepared by solvent displacement, adjusted with NaOH 0.05 M 
to pH 8, and then titrated with HCl 0.05 M  and 0.005 M using a MPT-2 Malvern Autotitrator (n = 
3; error bars represent ±SD). 
Figure 4. SEM (left) and AFM images (right) of freeze-dried PLA-DEX-OX4 nanoparticles prepared 
via solvent displacement. 
Figure 5. Release profiles from loaded PLA-DEX-OX4 nanoparticles (1 mg/ml) in PBS (pH 7.4; 
saline 0.9 %) at 37 °C for: A) FITC; B) Rhodamine B; C) Doxorubicin (n=3, ±SD).  
Figure 6. Results of toxicity studies following incubation of different types of brain endothelial cells 
with nanoparticles formulated from poly(lactic acid)-graft-alkylglyceryldextran derivatives ((PLA-
DEX-OX4 - poly(lactic acid)-graft-alkylglyceryldextran, PLA-DEX-OX8 - poly(lactic acid)-graft-
butylglyceryldextran, PLA-DEX - poly(lactic acid)-graft-dextran), at different incubation times and 
using different types of cytotoxicity assays (PBS and, digitonin as controls; error bars represent 
standard deviation): A) bEnd3 cells incubated with 1 mg/mL of nanoparticles for 24 h; MTT assay 
(n=18, ±SD); B) hCMEC/D3 cells incubated with nanoparticles for 3 h, dose response, PrestoBlue 
assay (n=12, ±SD); C) hCMEC/D3 cells incubated with PLA-DEX-OX4 nanoparticles for 24 h, dose 
response (1 – 4 mg/mL); PrestoBlue assay (n=12, ±SD). 
Figure 7. Confocal microscopy images (a - fluorescence 543 nm; b - differential interference 
contrast (Nomarski); c – merged; 100m scale bar) of somite microtome sections following 
injection in chicken embryos with: 1) nanoparticles loaded with Rhodamine B (1.5 % w/w); 2) 
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Rhodamine B solution of equivalent dose. Image 3) shows an illustration of somites (adapted from 
ref.
46
) and the site of our injections (1mm scale bar). 
Figure 8. Confocal microscope images of bEnd3 cells following incubation with PLA-DEX-OX4 
nanoparticles (1 mg/mL) for 3 h (1 a-c), with Rhodamine B solution (equivalent concentration of 
dye) used as control (2 a-c): a) images of cell nuclei, Hoechst-counterstained, in blue (405 nm 
laser); b) images of Rhodamine B label, in red (543 nm laser), c) merged images (405 nm and 543 
nm lasers); 50 m scale bars. Image (3) is a three dimensional Z stack projection of optical sections 
of bEnd3 cells containing PLA-DEX-OX4 nanoparticles loaded with Rhodamine B (20m scale 
bar). 
 
Figure 9. Electric Cell-substrate Impedance Sensing (ECIS) plot of the variation of TEER values (as 
%, relative to control) at 2000 Hz using A) bEnd3 and B) hCMEC/D3 brain endothelial cell 
monolayers cultured on 8W10E test plates, following exposure to and then removal of 
nanoparticles(timepoints indicated by orange arrows) prepared from PLA-DEX and PLA-DEX-OX4, 
in dose-response experiments. Nanoformulations were added to the cells at 48 h and removed at 72 
h, after which the cells were allowed to recover for a further 48 h. Data presented as means of three 
wells (n = 3), for each condition of a representative measurement (error bars represent ±SE). 
Untreated cells (PBS, no nanoparticles added) were employed as control. 
 
Figure 10. The effect of nanoformulations on the FITC-dextran (150 KDa) translocation through 
brain endothelial cell layers, at different concentrations: A) mouse bEnd3 cells model; B) human 
hCMEC/D3 cells model. Nanoparticles were prepared from PLA-DEX-OX4, and from PLA-DEX; 
FITC-dextran was used as a control (n = 5, ±SD). 
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